Clinical trial
A Multicentre, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
NCT05563467 is registered in ClinicalTrials.gov with Maria Sklodowska-Curie National Research Institute of Oncology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicentre, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
- Lead sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- January 31, 2023
- Completion date
- May 31, 2027
- Enrollment
- 24 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.